Literature DB >> 16395668

Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing.

Jessie Auclair1, Marie Pierre Busine, Claudine Navarro, Eric Ruano, Gilles Montmain, Françoise Desseigne, Jean Christophe Saurin, Christine Lasset, Valérie Bonadona, Sophie Giraud, Alain Puisieux, Qing Wang.   

Abstract

A substantial proportion of MLH1 and MSH2 gene mutations in hereditary nonpolyposis colon cancer syndrome (HNPCC) families are characterized by nucleotide substitutions, either within the coding sequence (missense or silent mutations) or in introns. The question of whether these mutations affect the normal function of encoding mismatch DNA repair proteins and thus lead to the predisposition to cancer is determinant in genetic testing. Recent studies have suggested that some nucleotide substitutions can induce aberrant splicing by disrupting cis-transcription elements such as exonic enhancers (ESEs). ESE disruption has been proposed to be the mechanism that underlies the presumed pathological missense mutations identified in HNPCC families. To investigate the prevalence of aberrant splicing resulting from nucleotide substitutions, and its relevance to predicted ESEs, we conducted a systematic RNA screening of a series of 60 patients who carried unrelated exonic or intronic mutations in MLH1 or MSH2 genes. Aberrant splicing was found in 15 cases, five of which were associated with exonic mutations. We evaluated the link between those splicing mutations and predicted putative ESEs by using the computational tools ESEfinder and RESCUE-ESE. Our study shows that the algorithm-based ESE prediction cannot be definitely correlated to experimental observations from RNA screening. By using minigene constructs and in vitro transcription assay, we demonstrated that nucleotide substitutions are the direct cause of the splicing defect. This is the first systematic screening for the effect of missense and silent mutations on splicing in HNPCC patients. The pathogenic splicing mutations identified in this study will contribute to the assessment of "unclassified variants" in genetic counseling. Our results also suggest that one must use caution when determining the pathogenic effect of a missense or silent mutation using ESE prediction algorithms. Analysis at the RNA level is therefore necessary. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395668     DOI: 10.1002/humu.20280

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  39 in total

Review 1.  Clinical correlation and molecular evaluation confirm that the MLH1 p.Arg182Gly (c.544A>G) mutation is pathogenic and causes Lynch syndrome.

Authors:  Michael P Farrell; David J Hughes; Ian R Berry; David J Gallagher; Emily A Glogowski; Stewart J Payne; Michael J Kennedy; Róisín M Clarke; Susan A White; Cian B Muldoon; Fiona Macdonald; Pauline Rehal; Danielle Crompton; Solvig Roring; Sarah T Duke; Trudi McDevitt; David E Barton; Shirley V Hodgson; Andrew J Green; Peter A Daly
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

2.  Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation.

Authors:  Patrizia Lastella; Margherita Patruno; Giovanna Forte; Alba Montanaro; Carmela Di Gregorio; Carlo Sabbà; Patrizia Suppressa; Adalgisa Piepoli; Anna Panza; Angelo Andriulli; Nicoletta Resta; Alessandro Stella
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

3.  Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer.

Authors:  Karsten Bork Nielsen; Suzette Sørensen; Luca Cartegni; Thomas Juhl Corydon; Thomas Koed Doktor; Lisbeth Dahl Schroeder; Line Sinnathamby Reinert; Orly Elpeleg; Adrian R Krainer; Niels Gregersen; Jørgen Kjems; Brage Storstein Andresen
Journal:  Am J Hum Genet       Date:  2007-01-18       Impact factor: 11.025

4.  Functional characterization of rare missense mutations in MLH1 and MSH2 identified in Danish colorectal cancer patients.

Authors:  Lise Lotte Christensen; Reetta Kariola; Mari K Korhonen; Friedrik P Wikman; Lone Sunde; Anne-Marie Gerdes; Henrik Okkels; Carsten A Brandt; Inge Bernstein; Thomas V O Hansen; Rikke Hagemann-Madsen; Claus L Andersen; Minna Nyström; Torben F Ørntoft
Journal:  Fam Cancer       Date:  2009-08-21       Impact factor: 2.375

5.  Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes.

Authors:  Monika Morak; Kerstin Schaefer; Verena Steinke-Lange; Udo Koehler; Susanne Keinath; Trisari Massdorf; Brigitte Mauracher; Nils Rahner; Jessica Bailey; Christiane Kling; Tanja Haeusser; Andreas Laner; Elke Holinski-Feder
Journal:  Eur J Hum Genet       Date:  2019-07-22       Impact factor: 4.246

6.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

7.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.

Authors:  David E Goldgar; Douglas F Easton; Graham B Byrnes; Amanda B Spurdle; Edwin S Iversen; Marc S Greenblatt
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.

Authors:  H Ziada-Bouchaar; K Sifi; T Filali; T Hammada; D Satta; N Abadi
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

Review 9.  Genotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families.

Authors:  Christopher D Heinen
Journal:  Mutat Res       Date:  2009-09-17       Impact factor: 2.433

10.  Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.

Authors:  Anirban Ghosh; Hemalatha Kuppusamy; Linda M Pilarski
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.